Andreja Rehberger Likozar

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 9

Top Topics

Cardiovascular Events

Inflammatory Response

Coronary Artery Disease

Ejection Fraction

Top Venues

International journal of molecular sciences

Journal of cardiovascular development and disease

Proceedings of the National Academy of Sciences of the United States of America

This page only lists publications with an associated author ORCID identifier.

Publications

Sabina Ugovšek, Andreja Rehberger Likozar, Tina Levstek, Katarina Trebušak Podkrajšek, Janja Zupan, Miran Šebeštjen
Haplotype of the Lipoprotein(a) Gene Variants rs10455872 and rs3798220 Is Associated with Parameters of Coagulation, Fibrinolysis, and Inflammation in Patients after Myocardial Infarction and Highly Elevated Lipoprotein(a) Values. International journal of molecular sciences 25 (2) (2024)
Sabina Ugovšek, Andreja Rehberger Likozar, Tina Levstek, Katarina Trebušak Podkrajšek, Janja Zupan, Miran Šebeštjen
Haplotype of the Lipoprotein(a) Gene Variants rs10455872 and rs3798220 Is Associated with Parameters of Coagulation, Fibrinolysis, and Inflammation in Patients after Myocardial Infarction and Highly Elevated Lipoprotein(a) Values. International journal of molecular sciences 25 (2) (2024)
Sabina Ugovšek, Andreja Rehberger Likozar, Tina Levstek, Katarina Trebušak Podkrajšek, Janja Zupan, Miran Šebeštjen
Haplotype of the Lipoprotein(a) Gene Variants rs10455872 and rs3798220 Is Associated with Parameters of Coagulation, Fibrinolysis, and Inflammation in Patients after Myocardial Infarction and Highly Elevated Lipoprotein(a) Values. International journal of molecular sciences 25 (2) (2024)
Tina Levstek, Tina Karun, Andreja Rehberger Likozar, Miran Šebeštjen, Katarina Trebušak Podkrajšek
Interplay between microRNAs, Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), and Lipid Parameters in Patients with Very High Lipoprotein(a) Treated with PCSK9 Inhibitors. Genes 14 (3) (2023)
Tina Levstek, Tina Karun, Andreja Rehberger Likozar, Miran Šebeštjen, Katarina Trebušak Podkrajšek
Interplay between microRNAs, Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), and Lipid Parameters in Patients with Very High Lipoprotein(a) Treated with PCSK9 Inhibitors. Genes 14 (3) (2023)
Tina Levstek, Tina Karun, Andreja Rehberger Likozar, Miran Šebeštjen, Katarina Trebušak Podkrajšek
Interplay between microRNAs, Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), and Lipid Parameters in Patients with Very High Lipoprotein(a) Treated with PCSK9 Inhibitors. Genes 14 (3) (2023)
Max Lenz, Manuel Salzmann, Cosmin I Ciotu, Christoph Kaun, Konstantin A Krychtiuk, Andreja Rehberger Likozar, Miran Šebeštjen, Laura Göderle, Sabine Rauscher, Zoriza Krivaja, Christoph J Binder, Kurt Huber, Christian Hengstenberg, Bruno Karl Podesser, Michael J M Fischer, Johann Wojta, Philipp J Hohensinner, Walter S Speidl
Pharmacologic modulation of intracellular Na + concentration with ranolazine impacts inflammatory response in humans and mice. Proceedings of the National Academy of Sciences of the United States of America 119 (29) (2022)
Tina Levstek, Nik Podkrajšek, Andreja Rehberger Likozar, Miran Šebeštjen, Katarina Trebušak Podkrajšek
The Influence of Treatment with PCSK9 Inhibitors and Variants in the CRP (rs1800947), TNFA (rs1800629), and IL6 (rs1800795) Genes on the Corresponding Inflammatory Markers in Patients with Very High Lipoprotein(a) Levels. Journal of cardiovascular development and disease 9 (5) (2022)
Katja Hrovat, Andreja Rehberger Likozar, Janja Zupan, Miran Šebeštjen
Gene Expression Profiling of Markers of Inflammation, Angiogenesis, Coagulation and Fibrinolysis in Patients with Coronary Artery Disease with Very High Lipoprotein(a) Levels Treated with PCSK9 Inhibitors. Journal of cardiovascular development and disease 9 (7) (2022)